bioTheranostics, Inc.
Genomic assays for oncology patient stratification and personalized treatment selection
- Sector
- Medtech
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $20M, Feb 2016
- Total capital
- $20M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $20M
- 1 Form D · last Feb 2016
- 129 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 18 pending · first 2017
- Rank in peer group#20 of 160
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$20M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 160 peers
Line = medianMedtech · Instrument
- Granted patents#20 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alejandro SanchezDirectorNamed in SEC Form D filings
- David KabakoffDirectorNamed in SEC Form D filings
- Eric BednarskiDirectorNamed in SEC Form D filings
- Nicholas BarthelemyExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 26- GrantedNeuroendocrine TumorsUSPTOUS 12,595,516
- PendingIntegration Of Tumor Characteristics With Breast Cancer IndexUSPTOApplication 19002028
- GrantedIntegration Of Tumor Characteristics With Breast Cancer IndexUSPTOUS 12,215,390
Show all 26 patent records
- Neuroendocrine TumorsApr 7, 2026 · US 12,595,516Granted
- Integration Of Tumor Characteristics With Breast Cancer IndexJul 3, 2025 · Application 19002028Pending
- Integration Of Tumor Characteristics With Breast Cancer IndexFeb 4, 2025 · US 12,215,390Granted
- Identification Of Tumors And TissuesJan 26, 2023 · Application 17854909Pending
- Neuroendocrine TumorsJan 10, 2023 · US 11,549,148Granted
- Integration Of Tumor Characteristics With Breast Cancer IndexDec 20, 2022 · US 11,530,448Granted
- Identification Of Tumors And TissuesAug 30, 2022 · US 11,430,544Granted
- Determining Tumor OriginApr 7, 2022 · Application 17502355Pending
- Identification Of TumorsJun 18, 2020 · Application 16701000Pending
- Identification Of TumorsJan 21, 2020 · US 10,538,816Granted
- Predicting Likelihood Of Response To Combination TherapyApr 9, 2019 · US 10,253,369Granted
- Determining Tumor OriginMar 15, 2018 · Application 15582125Pending
- Determining Tumor OriginJun 6, 2017 · US 9,670,553Granted
- Predicting Breast Cancer RecurrenceJul 23, 2015 · Application 14483108Pending
- Neuroendocrine TumorsNov 27, 2014 · Application 14223473Pending
- Identification of TumorsJan 24, 2013 · Application 13626078Pending
- Biomarker Assay To Select Breast Cancer TherapyApplication 63377987Pending
- Biomarker Assay To Select Breast Cancer TherapyApplication 19116291Pending
- Biomarker Assay To Select Breast Cancer TherapyApplication 63382457Pending
- Biomarker Assay To Select Breast Cancer TherapyApplication 63383470Pending
- Integration Of Tumor Characteristics With Breast Cancer IndexApplication PCTUS2016061568Pending
- Biomarker Assay To Select Breast Cancer TherapyApplication PCTUS2023075506Pending
- Integration Of Tumor Characteristics With Breast Cancer IndexApplication 62265964Pending
- Predicting Likelihood Of Response To Combination TherapyApplication PCTUS2015033047Pending
- Neuroendocrine TumorsApplication PCTUS2014031587Pending
- Determining Tumor OriginApplication PCTUS2011031870Pending
Related companies, and why
- Phantom Neuro Inc.Similar federal contract value in Medtech · null in contracts
- Relentless Health Inc.Similar federal contract value in Medtech · null in contracts
- Oklahoma Proton Center LLCSimilar federal contract value in Medtech · null in contracts
- Roadio, Inc.Similar federal contract value in Medtech · null in contracts
- MILESTONE SCIENTIFIC INC.Similar federal contract value in Medtech · null in contracts
- Spartan Bioscience Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .